Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by State University of New York - Upstate Medical University
Sponsor:
Information provided by (Responsible Party):
State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier:
NCT01799018
First received: December 12, 2012
Last updated: February 22, 2013
Last verified: February 2013
  Purpose

The purpose of this study is to determine the role of Proteomics and Metallomics in Cerebral Vasospasm following Subarachnoid Hemorrhage


Condition
Subarachnoid Hemorrhage
Cerebral Vasospasm
Hydrocephalus

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage

Resource links provided by NLM:


Further study details as provided by State University of New York - Upstate Medical University:

Primary Outcome Measures:
  • Protein identification and concentration [ Time Frame: For the duration of CSF drainage, or until the 21st day after admission. ] [ Designated as safety issue: No ]
  • Metal ion identification and concentration [ Time Frame: For the duration of CSF drainage, or until the 21st day after admission. ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Cerebrospinal Fluid (CSF)


Estimated Enrollment: 35
Study Start Date: April 2011
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
SAH Patients
Patients admitted with the diagnosis of aneurismal subarachnoid hemorrhage (SAH) and cerebral angiogram negative SAH who would need to have the external ventricular drain (EVD) placed for the management of hydrocephalus.
Control Patients
Patients with non-hemorrhagic brain pathology such as posterior fossa tumor or stroke who will have the CSF sampling for diagnostic or therapeutic purposes.

  Eligibility

Ages Eligible for Study:   18 Years to 89 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients admitted to University Hospital.

Criteria

Inclusion Criteria:

  • Non traumatic SAH documented by CT scan
  • Patient with SAH who would need external ventricular drain (EVD) for the management of hydrocephalus
  • Patients with normal pressure Hydrocephalus that require an external drain
  • Control (non - hemorrhagic) group - CSF collected from patients with posterior fossa tumor or stroke with EVD in place for the management of hydrocephalus.

Exclusion Criteria:

  • Recent infection within last 1 month of presentation- can increase inflammatory markers
  • Recent surgery or acute myocardial infarction within last 1 month of presentation
  • Age > 89 years or < 18 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01799018

Contacts
Contact: Mark R Villwock, MS 315-464-5502 villwocm@upstate.edu

Locations
United States, New York
State University of New York Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Mark R Villwock, MS    315-464-5502    villwocm@upstate.edu   
Principal Investigator: Eric M Deshaies, MD         
Sponsors and Collaborators
State University of New York - Upstate Medical University
Investigators
Principal Investigator: Eric M Deshaies, MD SUNY Upstate Medical University - Neurosurgery
  More Information

No publications provided

Responsible Party: State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier: NCT01799018     History of Changes
Other Study ID Numbers: IRB#225490
Study First Received: December 12, 2012
Last Updated: February 22, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by State University of New York - Upstate Medical University:
Xanthine Oxidase
Cerebrospinal fluid

Additional relevant MeSH terms:
Hydrocephalus
Hemorrhage
Subarachnoid Hemorrhage
Vasospasm, Intracranial
Pathologic Processes
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Intracranial Hypertension
Intracranial Hemorrhages
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 26, 2014